Navigation Links
Industry leaders join together for historic Accelerating Cancer Cures Research Symposium
Date:3/6/2012

New York, NY (March 5, 2012) Today, the Damon Runyon Cancer Research Foundation held its first Accelerating Cancer Cures Research Symposium, focused on rebuilding the ranks of physician-scientists specially trained to translate laboratory discoveries into new cancer therapies. The event, held at Pfizer Inc headquarters, brought together academic scientists and other leading pharmaceutical companies, including Eli Lilly and Company, Celgene, Genentech, Merck, and Millennium: The Takeda Oncology Company.

The symposium is the first of its kind since Damon Runyon, a New York-based foundation, launched its Accelerating Cancer Cures program in June 2011. Accelerating Cancer Cures is a five-year, multi-million dollar project that will train a new generation of exceptional clinical investigators capable of translating the latest scientific discoveries into new diagnostics and therapeutics for cancer patients. The initiative also eliminates barriers to progress by fostering communication and collaboration between academia and industry. It is supported by some of the world's leading companies and The Pharmaceutical Research and Manufacturers of America (PhRMA).

"We risk losing tremendous ground in our effort to find cures for cancer if we cannot attract new talent and new ideas to clinical research," said Damon Runyon Cancer Research Foundation President and CEO Lorraine Egan when the program launched. "Our best hope for crucial breakthroughs to prevent, diagnose and treat cancer lies with the committed young scientists who will be able to pursue critical translational research thanks to this effort."

Scientists from the nation's leading research institutions, including the Dana-Farber Cancer Institute, Fred Hutchinson Cancer Research Center, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, and the University of North Carolina, Chapel Hill, traveled to New York to attend.

Pfizer Vice President Jamey R. Skillings, MD, MSc, MBA,
'/>"/>

Contact: Todd Brogan
todd.brogan@damonrunyon.org
212-455-0552
Damon Runyon Cancer Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. ClearWay Minnesota(SM) Shines a Spotlight on a Reinvented Tobacco Industry
2. Industry Recognizes the Regence Health Engine for Excellence in Creativity, Innovation and Information
3. Chocolate Industry Leaders Sign Agreement, Align on Path Towards Increasing Consumer Availability & Consistency of Beneficial Cocoa Flavanols
4. San Diego State University and BIOCOM Institute Receive $4.95 Million Grant: The BRIDGE Project, Linking Education to Employment in San Diegos Life Sciences Industry
5. Language Service Leader Expands to Meet Booming, Global Industry Demand.
6. Vestara and EXP Pharmaceutical Services Corp. Announce Partnership Making Available Industry's Only Automated Pharmaceutical Waste Management Solution to over 5,000 U.S. Hospitals
7. Pelosi, Senior Democrats Remarks at News Conference on Repealing Health Insurance Industry Anti-Trust Exemption
8. Researchers at No. 1-Ranked U.S. Childrens Hospital Work with Industry to Develop a Child Crash Dummy thats More True-to-Life
9. Innovative Medical Alert Device Sets a New Standard in PERS Industry
10. Dairy Industry Raises a Glass of Milk to Lets Move! Campaign
11. LG Electronics Provides a Dose of HD for the Healthcare Industry at HIMSS 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... he says will reveal biblical truth and expose popular lies regarding proper relationships according ... Don’t Have Sex”, immediately goes into the core of the subject by explaining why ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to ... the 19th sweetFrog store located in the Lone Star State. The premium frozen yogurt ... in 2014. , The store, which opened July 1 at Duke’s Travel Plaza, is ...
(Date:7/2/2015)... , ... July 02, 2015 , ... With summer in full swing, Americans are flocking ... one of the top spots for fishing in the world, and it’s easy to understand ... Ontario, Canada has great fish. , Recreational fishing is a huge industry, and Americans ...
(Date:7/2/2015)... ... July 02, 2015 , ... Global leader and compression innovator, ... designed for men. , For style that’s quick on its feet, men will ... is great news for men everywhere because a simple change in socks can dramatically ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... provides comprehensive information on the pipeline products with comparative analysis of the ... therapy (NPWT) with 22 market data tables and 4 figures, spread across ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4
... use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) ... men with prostate cancer, say researchers at Vanderbilt University. ... Health Study included 1,277 participants referred to a urologist ... of the men reported taking an NSAID, mostly aspirin ...
... long-term, randomized clinical trial that included 14,641 physicians who were ... given 400 IU of vitamin E every other day or ... its placebo. , Researchers followed these patients for up ... rates of completion of annual questionnaires, and the confirmation of ...
... characterized as being in "denial" not recognizing the ... to be a form of deception, emerging research suggests ... dysfunction similar to that observed in other neuropsychiatric illnesses. ... relevant research during a symposium on "Impaired Insight into ...
... DPL™ Therapy System for temporary relief of pain. , ... ... announced today that the U.S. Food and Drug Administration (FDA) cleared ... of muscle spasms, temporary relief of minor muscle and joint aches, ...
... A protein known to inhibit the growth of ovarian ... themselves until they die, researchers at The University of Texas ... issue of Cancer Research . , The research team ... is an independent indicator of a woman,s prospects for surviving ...
... Finding may explain why treatment and outcomes are different among ... lung tumors tend to have a different genetic makeup in ... treatment and outcomes are different among races, a new study ... to carry more copies of the epidermal growth factor receptor ...
Cached Medicine News:Health News:Men who take aspirin have significantly lower PSA levels 2Health News:Men who take aspirin have significantly lower PSA levels 3Health News:No protective effect on cancer from long-term vitamin E or vitamin C supplementation 2Health News:'Insight' deficit may explain denial in drug addiction 2Health News:'Insight' deficit may explain denial in drug addiction 3Health News:FDA Clears the DPL (Deep Penetrating Light) Therapy System for Over-the-Counter - Home Use 2Health News:Protein compels ovarian cancer cells to cannibalize themselves 2Health News:Lung Cancer Genetics Different in Black Patients: Study 2
(Date:7/2/2015)... , July 2, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... shares have been approved for listing and trading on the ... ESSA will begin trading on NASDAQ on July 9, 2015.  ... Exchange under the symbol "EPI". As a result ... each of the Company,s outstanding special warrants issued on January ...
(Date:7/2/2015)... July 2, 2015  Fort Lauderdale-based investment banking ... announce that its Consumer Group completed the sale ... Group plc (ISE: KRZ) ("Kerry"), one of the ... systems, as well as functional ingredients and actives ... Farlie Turner served as the exclusive financial advisor ...
(Date:7/2/2015)... NEW YORK , July 2, 2015 /PRNewswire/ ... of a conspicuously high-growth market segment in hematology ... research publisher said that Roche,s recent unveiling of its ... into the cobas m 511 hematology ... not only capture growth enjoyed by current leader ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3
... percent of patients treated with VELCADE, cyclophosphamide,and ... Greece, June 28, 2007 /PRNewswire-FirstCall/ -- Millennium,Pharmaceuticals, ... results,from clinical trials of VELCADE based therapies ... (CR) rates in previously,treated multiple myeloma (MM) ...
... 29, 2007 /PRNewswire/ --,The European Myeloma Platform (EMP) ... (lenalidomide) plus the,steroid dexamethasone shows median survival of ... from two large randomized,controlled Phase III trials that ... sites worldwide. These updated results,were presented at the ...
Cached Medicine Technology:Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 2Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 3Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 4Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 5Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 6The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: